Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: zalesky who wrote (7916)	6/14/1999 8:15:00 AM
From: Manly	Read Replies (1) \| Respond to of 9523

Z, The interesting point with MM's is that typically when they love a stock it's time to sell and when they start bashing a stock after it's gone down 33% it's time to buy. Should have sold at $150; however, this is one of our core long term holdings and we are not treating it like an internet stock. Also have an order in the low $90's if we're lucky enough to pick up more shares. PFE is not going away overnight, if I was getting ready to retire that would be another sotry. We're in our 30's and have a few more years to go until retirement. PFE will look real sweat in 10-15 years from now start with our 1500 shares (soon to be 4500) unless we're lucky enough to pick up more! Have a good week, it's going to be crazy - me I'm not going to watch, just go to work and not read how the dooms dayers state how PFE is dead. Shorting here is pretty crazy with the 3 for 1 a couple weeks away! Glenn

To: zalesky who wrote (7916)	6/14/1999 9:41:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Merck's Vioxx Prescriptions Total 8,000 After Two Weeks Bloomberg News June 14, 1999, 6p.m. ET Merck's Vioxx Prescriptions Total 8,000 After Two Weeks Washington, June 14 (Bloomberg) -- Merck & Co.'s new arthritis drug Vioxx is off to a slower start than rival Monsanto Co.'s Celebrex, according to prescription data compiled by IMS Health Inc., though analysts cautioned it was too early to draw conclusions from the numbers. According to data from the week ended June 4, Vioxx has generated 8,003 prescriptions in its first two weeks on the market, 1,500 less than the 9,527 prescriptions written for Celebrex during its first two weeks on the market earlier this year, IMS said. Though prescription numbers are being closely watched in an effort to assess how the two drugs will compete in the $8-billion- a-year arthritis-painkiller market, Hambrecht & Quist analyst Alex Zisson said it's premature to compare the two drugs. ''The Merck sales force isn't even out there yet,'' said Hambrecht & Quist analyst Alex Zisson. ''It takes a couple of months into a launch into to gauge what the long-term prospects are.'' Celebrex, co-marketed by Monsanto and Pfizer Inc., had one of the most successful product introductions in drug history when the drug hit pharmacies in January, and the drug is on pace to do well over $1 billion in sales in 1999, a milestone that would gfoive the drug ''blockbuster'' status. Eventually, analysts say, Vioxx and Celebrex could each bring in $2 billion a year. The potential sales for the drugs are seen a boon for both companies. Celebrex sales drove Monsanto sales in the first quarter of 1999, and Merck hopes to build Vioxx into a blockbuster that can offset sales losses for four drugs -- worth about $5 billion a year -- that will lose patent protection by 2001. The drugs are members of a new class of painkillers, known as Cox-2 inhibitors, which as effective as older painkillers like aspirin or ibuprofen and gentler on the stomach.